Valsartan

May be taken with or without food.

Biliary cirrhosis, cholestasis. Severe hepatic impairment. Pregnancy. Concomitant use with aliskiren in patients with diabetes mellitus or renal impairment (GFR <60 mL/min/1.73 m²).

Patient with aortic or mitral stenosis, hypertrophic obstructive cardiomyopathy, post-MI, heart failure; bilateral or unilateral renal artery stenosis, volume and/or Na depletion; ascites due to cirrhosis or refractory ascites, primary hyperaldosteronism; history of angioedema. Patients undergoing surgery. Black patients. The oral solution of valsartan has higher bioavailability and peak plasma concentration than the tab/cap preparation; therefore, tab/cap and oral solution are not bioequivalent on a mg:mg basis. Renal and mild to moderate hepatic impairment. Children. Lactation. Patient Counselling This drug may cause dizziness or weariness, if affected, do not drive or operate machinery. Monitoring Parameters Monitor blood pressure, electrolytes (e.g. serum K levels), and renal function regularly during therapy. Assess for signs of angioedema.

Significant: Acute kidney injury, increased serum creatinine, hyperkalaemia, hypotension, angioedema. Blood and lymphatic system disorders: Neutropenia, thrombocytopenia. Ear and labyrinth disorders: Vertigo. Gastrointestinal disorders: Nausea, abdominal pain, diarrhoea. General disorders and administration site conditions: Fatigue, asthenia. Immune system disorders: Hypersensitivity including serum sickness. Investigations: Increased liver enzymes, increased BUN, decreased Hb and haematocrit. Metabolism and nutrition disorders: Hyponatraemia. Musculoskeletal and connective tissue disorders: Back pain, myalgia, arthralgia. Nervous system disorders: Dizziness, headache, orthostatic dizziness. Respiratory, thoracic and mediastinal disorders: Cough. Skin and subcutaneous tissue disorders: Rash, pruritus, dermatitis bullous. Vascular disorders: Syncope, orthostatic hypotension, vasculitis.

Increased serum K levels with K-sparing diuretics (e.g. spironolactone, triamterene, amiloride), K supplements, K-containing salt substitutes, or other agents that may elevate serum K levels (e.g. heparin). May increase serum lithium concentration and toxicity. May reduce the antihypertensive effect and increase the risk of worsening renal function with NSAIDs including aspirin and selective COX-2 inhibitors. Systemic exposure may be increased with inhibitors of OATP1B1 (e.g. rifampicin, ciclosporin) and multidrug resistance protein 2 (MRP2) such as ritonavir.

Angiotensin II Antagonists

C09CA03 - valsartan ; Belongs to the class of angiotensin II antagonists. Used in the treatment of cardiovascular disease.